FTRE vs. RDNT, GH, VCYT, VRDN, EXAS, NTRA, XENE, SHC, PRCT, and TXG
Should you be buying Fortrea stock or one of its competitors? The main competitors of Fortrea include RadNet (RDNT), Guardant Health (GH), Veracyte (VCYT), Viridian Therapeutics (VRDN), Exact Sciences (EXAS), Natera (NTRA), Xenon Pharmaceuticals (XENE), Sotera Health (SHC), PROCEPT BioRobotics (PRCT), and 10x Genomics (TXG). These companies are all part of the "medical" sector.
Fortrea (NASDAQ:FTRE) and RadNet (NASDAQ:RDNT) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking.
RadNet received 333 more outperform votes than Fortrea when rated by MarketBeat users. Likewise, 65.70% of users gave RadNet an outperform vote while only 47.06% of users gave Fortrea an outperform vote.
RadNet has a net margin of 1.28% compared to Fortrea's net margin of -4.11%. RadNet's return on equity of 5.05% beat Fortrea's return on equity.
RadNet has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than RadNet, indicating that it is currently the more affordable of the two stocks.
In the previous week, Fortrea had 23 more articles in the media than RadNet. MarketBeat recorded 35 mentions for Fortrea and 12 mentions for RadNet. RadNet's average media sentiment score of 0.39 beat Fortrea's score of 0.37 indicating that RadNet is being referred to more favorably in the news media.
77.9% of RadNet shares are owned by institutional investors. 0.1% of Fortrea shares are owned by company insiders. Comparatively, 4.4% of RadNet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Fortrea presently has a consensus target price of $35.57, indicating a potential upside of 29.12%. RadNet has a consensus target price of $57.25, indicating a potential downside of 0.35%. Given Fortrea's higher probable upside, research analysts plainly believe Fortrea is more favorable than RadNet.
Summary
RadNet beats Fortrea on 12 of the 18 factors compared between the two stocks.
Get Fortrea News Delivered to You Automatically
Sign up to receive the latest news and ratings for FTRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FTRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
